Thinking about a collaborative CRO to work with? Join us to learn more about Nexus Pharma.
Our clients use PDX models for later stage preclinical studies because they are more rigorous systems, clinically relevant, and significantly higher in their predictive value for meaningful biological responses.
If you are a preclinical scientist who wants to test drug resistant models, models with specific oncogene profiles or demonstrate therapeutic efficacy, this webinar will get you up to speed on PDX models.
Join Dr. Vladimir Khazak, PhD, CSO of NexusPharma, for an eye opening look at NexusPharma’s growing collection of PDX models.